CytoDyn
CYDY · OTCQB · United States
Share price · CYDY
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CYDY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 13 Aug 2026+5.3%
Nothing announced by CYDY that day or the session before.
- 23 Apr 2026-11.8%
- 16 Apr 2026+8.8%
Nothing announced by CYDY that day or the session before.
- 13 Apr 2026+13.8%
Nothing announced by CYDY that day or the session before.
- 26 Mar 2026+11.5%
Nothing announced by CYDY that day or the session before.
- 16 Mar 2026+11.5%
Nothing announced by CYDY that day or the session before.
- 26 Feb 2026-7.7%
Nothing announced by CYDY that day or the session before.
- 19 Feb 2026+8.0%
Nothing announced by CYDY that day or the session before.
- 17 Nov 2025+14.8%
Nothing announced by CYDY that day or the session before.
- 3 Nov 2025+8.3%
Share of unusual movement by asset
For each asset, the share of CYDY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2/3 | CCR5 co-receptorMonoclonal antibody | Alzheimer's DiseaseHIVColorectal Cancer Metastatic Colorectal Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
January 2028 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | — | $16M | $20M-$7.7M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | — | $16M | $4.7M-$5.5M operating cash flow | report ↗ |
| 2025-Q4 | — | — | $5.0M | $23M-$4.3M operating cash flow | report ↗ |
| 2025-Q3 | — | — | $9.3M | $5.5M-$2.5M operating cash flow | report ↗ |
| 2025-Q1 | — | — | $16M | $4.8M-$5.0M operating cash flow | report ↗ |
| 2024-Q4 | — | — | $21M | $4.8M-$3.6M operating cash flow | report ↗ |
| 2024-Q3 | — | — | $25M | —$5.4M operating cash flow | report ↗ |
| 2024-Q1 | — | $0.7M | $8.0M | $12M-$2.3M operating cash flow | report ↗ |
| 2023-Q4 | — | $1.1M | $6.7M | $9.6M-$2.5M operating cash flow | report ↗ |
| 2023-Q3 | — | $1.9M | $8.6M | $12M-$4.5M operating cash flow | report ↗ |
| 2023-Q1 | — | $0.9M | $11M | $14M-$6.2M operating cash flow | report ↗ |
| 2022-Q4 | — | $0.1M | $2.6M | $27M-$4.4M operating cash flow | report ↗ |
| 2022-Q3 | — | $0.6M | $4.7M | $21M-$11M operating cash flow | report ↗ |
| 2022-Q1 | — | $9.1M | $2.4M | $32M-$11M operating cash flow | report ↗ |
| 2021-Q4 | $0.2M | $9.0M | $8.9M | $37M-$29M operating cash flow | report ↗ |
| 2021-Q3 | <$0.1M | $14M | $6.5M | $31M-$32M operating cash flow | report ↗ |
Annual history (6 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-FY | — | — | $12M | $11M-$17M operating cash flow | report ↗ |
View 5 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | — | $12M | —-$8.8M operating cash flow | report ↗ |
| 2024-FY | — | $7.2M | $9.8M | $12M-$11M operating cash flow | report ↗ |
| 2023-FY | $0 | $2.6M | $9.1M | $20M-$25M operating cash flow | report ↗ |
| 2022-FY | $0.3M | $27M | $4.2M | $53M-$78M operating cash flow | report ↗ |
| 2021-FY | $0 | $58M | $34M | $39M-$118M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-20 | Hoffman Robert E. · Chief Executive Officer | Award / grant (derivative) | 2,500,000 | — | — | Form 4 |
| 2026-03-20 | Blok Tyler · Chief Legal Officer | Award / grant (derivative) | 3,249,794 | — | — | Form 4 |
| 2026-03-20 | Brunke Karen J · director | Award / grant (derivative) | 574,385 | — | — | Form 4 |
| 2026-03-20 | Dunlap Ryan · director | Award / grant (derivative) | 574,385 | — | — | Form 4 |
| 2026-03-20 | Hoffman Robert E. · Chief Financial Officer | Award / grant (derivative) | 4,874,691 | — | — | Form 4 |
| 2026-03-20 | Lalezari Jacob P · Chief Executive Officer | Award / grant (derivative) | 4,874,691 | — | — | Form 4 |
| 2026-03-20 | Ndhlovu Lishomwa C · director | Award / grant (derivative) | 574,385 | — | — | Form 4 |
| 2026-03-20 | SIMES STEPHEN M · director | Award / grant (derivative) | 574,385 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 8 reporting institutions held 0.3M shares ($84K, 0.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | NBC SECURITIES, INC. | 160,000 | $44K |
| 2 | Diversified Trust Co | 45,790 | $13K |
| 3 | Williams Jones Wealth Management, LLC. | 45,001 | $12K |
| 4 | Next Capital Management LLC | 25,000 | $7K |
| 5 | HORIZON FINANCIAL SERVICES, LLC | 18,200 | $5K |
| 6 | Ancora Advisors LLC | 9,488 | $3K |
| 7 | CAZ INVESTMENTS LP | 4,000 | $1K |
| 8 | VSM Wealth Advisory, LLC | 500 | $137 |